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Abstract: There are variety of anticancer treatments including chemotherapeutic drugs, which 
are known to induce cell growth arrest and apoptosis through DNA damage and cytoskeleton 
toxicity. Meanwhile, histone deacetylase (HDAC) inhibitors could apply their antitumor activ-
ity through chromatin remodeling and gene expression modulation that affect the cell cycle 
and survival pathways. This paper proposes an anticancer three-drug compound and discusses 
several challenging issues in relation to designing multidrug compounds that could possibly 
lead to molecular-targeted therapies.
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Introduction
There is accurate machinery that allows cells to recognize themselves and undertake 
speciﬁ  c tasks. This machinery represents the blueprint of various patterns of gene 
activation/inactivation throughout the cell cycle. It is mediated by numerous processes 
such as DNA methylation, adenosine triphosphate (ATP)-dependent chromatin remod-
eling, and post-translational modiﬁ  cations of histones, which include the acetylation 
and deacetylation of amino groups of lysine residues present in histone N-terminal 
tails. The set of chromatin modifying enzymes include one of the histone modiﬁ  ca-
tion enzymes, such as histone acetyltransferase (HAT), histone deacetylase (HDAC), 
histone methyltransferase (HMT), histone demethylase (HDMT), and histone kinase. 
HATs act as transcriptional coactivators, whereas HDACs act as transcriptional core-
pressor enzymes. Lack of expression or repression leads to an irregular outcome for the 
cell, including altered genetic programs and increased rate of cell transformation.
A number of silenced tumor suppressor genes are shown to be lost due to epi-
genetic inactivation rather than sequence damages, although, epigenetic changes 
cooperate with genetic changes to initiate the development of a cancer since they 
are mitotically heritable.1,2 Further, epigenetic irregularities are pharmacologically 
reversible as oppose to genomic damage.3 This fact provides an incentive to devote 
more efforts in designing combination drugs that eventually achieve epigenetic and 
molecular-targeted therapies.
Combination therapy
It is known that the whole epidermal growth factor receptor (EGFR) family of proteins 
contributes to tumor cell growth in numerous types of cancer. When activated by par-
ticular molecules that bind to their ligands, such receptors transmit a proliferation signal 
to the cell by initiating a cascade of internal molecular interactions. Cancer cells also 
secrete a variety of growth factors to attract the endothelial cells that build new blood 
vessels (ie, angiogenesis), which subsequently make tumors more difﬁ  cult to treat.
The tangle of signaling pathways leading from the receptors to the cellular pro-
cesses that actually cause a cell to divide or to resist suicide despite DNA damage is 
highly complex. As depicted in Figure 1, a potential drug compound may suppress the Therapeutics and Clinical Risk Management 2009:5 240
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growth of cancer cells by inducing either G1 or G2 arrest, 
DNA synthesis, apoptosis, and should have antitumor activ-
ity against various types of cancer. Synergistic inhibition of 
cell proliferation and induction of apoptosis is an important 
factor towards effective combination therapy.
A combination between HDAC inhibitors like NVPLAQ824 
and vascular endothelial growth factor (VEGF) receptor 2 kinase 
inhibitors like PTK787/ZK222584 has been demonstrated 
to have an antiangiogenic and antitumor effect.4 This drug 
combination resulted in a greater antitumor and antiangio-
genic effect in vitro and in vivo compared with single agents 
(ie, monotherapies).
Many HDAC inhibitors mediate their antitumor activity 
by chromatin remodeling and then followed by gene expres-
sion modulation. The antiproliferative effect of an HDAC 
inhibitor on tumor cells is supposed to correlate with the 
induction of a speciﬁ  c gene expression that mediate cell 
cycle arrest and/or apoptosis. In addition, HDAC inhibi-
tors may also repress gene expression by inducing protein 
acetylation. For example, induction of p21 and inhibition of 
survivin expression may compromise the proliferation and 
differentiation of endothelial cells.4
Mitogen-activated protein kinases (MAPK) and AKT 
(a serine/threonine kinase also known as protein kinase B) 
pathways play important roles in cell proliferation,5 and 
therefore a compound that induces apoptosis is also supposed 
to inhibit AKT and/or MAPK activation. In addition, MAPK 
plays a role of a signaling mediator of EGFR in blockade of 
apoptosis. This presumes a signiﬁ  cant contribution of MAPK 
in cell survival, since it is also activated by EGF stimulation 
independent of epidermal receptor growth factor 2 (ErbB2) 
and epidermal receptor growth factor 3 (ErbB3) signaling in 
human colon cancer (GEO) cells.6 Unknown mechanisms or 
pathways that react to the compensatory activation of EGFR 
in response to the down-regulation of ErbB2 phosphorylation 
need to be explored. Hence, this study investigates the com-
bination of an EGFR inhibitor with an HDAC inhibitor and 
subsequently analyze the corresponding level of inhibitory 
effects on ErbB2 phosphorylation. This combination therapy 
is discussed and analyzed later in this paper.
A drug’s antitumor and antiangiogenesis effect needs 
to be correlated with the down-regulation of angiogenesis-
related genes such as VEGF and survivin.7,8 This type of 
drug also needs to modulate the expression of multiple genes 
that contribute in tumor development and angiogenesis, and 
it is required to induce other inhibition of VEGF signaling 
and angiogenesis as it is depicted in Figure 1. Further, the 
design of a potential compound with an antitumor effect must 
affect tumor growth by acting on independent and parallel 
pathways. A combination therapy should induce cell cycle 
arrest by gene expression modulation in epithelial tumor 
and endothelial cells. As a result, the newly designed drug 
has the potential to be tailored for individual patients. For 
instance, this therapy can target patients with tumors that 
are dependent upon VEGF, angiogenesis-related genes, 
EGFR, and ErbB2. This type of drug represents a potential 
molecular targeted therapy that is also called key personal-
ized medicine product.
Clinical trials of multidrug 
compounds
During a phase I study, a combination of trabectedin 
and pegylated liposomal doxorubicin (PLD) was tested 
in 36 patients with advanced malignancies.9 An overall 
response rate of 16.7% was reported including one complete 
response (CR) and f ive partial responses (PR), and 39% had 
Potential compound  Tumor proliferation cells 
& VEGF
Proliferation survival  
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Figure 1 Representation of concomitant molecular changes after combination treatment with a potential compound: Combination therapies with agents that target endothelial 
cells to block angiogenesis, EGFR/ERBB2, and histone deacetylase inhibitors to prevent tumor adaptation in cancer treatment warrants experimental studies.
Abbreviations: EGFR, epidermal growth factor receptor; ErbB2, epidermal receptor growth factor 2;   VEGF, vascular endothelial growth factor.Therapeutics and Clinical Risk Management 2009:5 241
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stable disease (SD). This study also conﬁ  rmed that trabectedin 
combined with PLD provides a potential clinical advantage, 
and it is generally well tolerated at therapeutic doses in pre-
treated patients with various tumor types.
A combination of immunosuppressive agents cyclophos-
phamide (CYC) and imatinib was evaluated in ﬁ  ve patients 
with advanced scleroderma-related interstitial lung disease.10 
This combination was tolerated and without major effects in 
all patients. From the two patients who completed one year of 
treatment, only one patient with mild restrictive lung disease 
showed improvement in pulmonary function. A phase I/II 
study tested the combination of geﬁ  tinib and rofecoxib in 
42 patients with nonsmall cell lung cancer.11 This study 
reported 2.3% CRs, 4.7% PRs, and 28.5% SDs. In addition, 
the treatment was also reported to be generally tolerated.
Thirty-one open-angle glaucoma patients who were 
insufﬁ  ciently controlled on latanoprost monotherapy, were 
given dorzolamide/timolol (DTFC), latanoprost/timolol 
fixed combination (LTFC), or a combination of DTFC 
and latanoprost.12 This study showed that the latter therapy 
considerably decreased the intraocular pressure (IOP). In 
a similar study, a combination therapy of brimonidine and 
timodol was effective in decreasing the IOP as opposed to 
monotherapy with brimonidin or timodol.13
In a phase I study, a combination of DNA-hypomethylating 
agent (5-AZA) and an HDAC inhibitor (valproic acid) was 
assigned to 55 patients with advanced cancer.14 This report 
showed 25% SDs in which the disease stabilized from four to 
12 months, and a considerable decrease in global DNA meth-
ylation and induction of histone acetylation were also observed. 
A phase II study of epigenetic therapy with hydralazine and 
magnesium valproate was reported.15 Seventeen patients 
were evaluable for toxicity and 15 for responses. Primary 
sites included cervix (3), breast (3), lung (1), testis (1), and 
ovarian (7) carcinomas. The results showed 26.7% PRs and 
53% SDs. The main toxicity was hematologic-related. Further, 
global DNA methylation, HDAC activity, and promoter 
demethylation were observed. A phase II trial was conducted 
to investigate clinical and molecular responses mediated by a 
histone deacetylase inhibitor (Depsipeptide FK228) in lung 
cancer patients. Nineteen patients were evaluable for toxicity 
and 18 for responses. This report showed neither signiﬁ  cant 
cardiac toxicities nor objective responses,16 since small does 
were assigned. However, a combination with other compounds 
warrants further evaluation in lung cancer patients.
The initial phase I/II trial of bortezomib and melphalan 
in 35 patients, who had progressed on relapsed or refractory 
multiple myeloma (MM) was reported.17 Responses were 
observed in 68% of the studied population including 6% 
CRs, 9% immunoﬁ  xation-positive CRs, 32% PRs, and 21% 
minimal response (MR). The combination of bortezomib and 
melphalan was reported to have a controllable toxicity and 
represent a compelling therapy candidate for MM patients. 
In a later report, a phase I/II study was conducted to assess 
the combination of arsenic trioxide/bortezomib/ascorbic acid 
(ABC) in 22 patients who had progressed on MM.18 This 
study showed that responses were only observed in 27% of 
the heavily pretreated study population including 9% PRs 
and 18% MRs. The ABC treatment was reported to be well 
tolerated by the majority of patients.
One thousand ninety-one patients with type 2 diabetes 
were treated with the combination therapy of sitagliptin and 
metformin.19 This regimen was reported tolerable amongst 
all patients and provided an additive glycemic improvements. 
Similar results were obtained when 217 type 2 diabetes 
patients were treated with the combination therapy of sulfo-
nylurea and metformin.20
A novel farnesyl protein transferase inhibitor (BMS-
214662) combined with paclitaxel and carboplatin was 
assigned in 30 patients with solid tumors.21 The purpose of 
this study was to investigate the toxicities, pharmacokinetics, 
and pharmacodynamics of BMS-214662 when combined 
with the other two compounds. This report showed no par-
ticular pharmacokinetic interaction between BMS-214662 
and paclitaxel, and the combination of BMS-214662 with 
paclitaxel and carboplatin was normally tolerated in solid 
tumors. This phase I trial also reported 3.3% PRs related to a 
taxane-resistant esophageal cancer, 6.6% PRs related to endo-
metrial and ovarian cancer, and 26.6% SDs. A phase I study 
also investigated the combination of P-glycoprotein inhibi-
tor (MS209) with docetaxel in patients with solid tumors.22 
This study showed the absence of strong pharmacokinetic 
interaction between the two compounds at moderate dose 
levels, and the combination therapy had a limited effect on 
docetaxel toxicity or pharmacokinetics.
In a phase Ib study, the combination of patupilone and 
carboplatin was tested in 26 patients with recurrent platinum-
sensitive ovarian cancer.23 Tumor response was assessable 
by response evaluation criteria in solid tumors in 17 patients 
including 6% CRs and 59% PRs. This report showed that 
the treatment was generally tolerable and proved to have an 
antitumor activity.
The link between human epidermal growth factor 
receptor 2 (Her-2) and VEGF was reported to have a major 
role in predicting clinical outcome in primary breast cancer.24 
Consequently, various combination therapies were assessed Therapeutics and Clinical Risk Management 2009:5 242
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against these two proteins when treating breast cancers with 
Her-2 overexpression. A phase I study using a combina-
tion of bevacizumab and trastuzumab in nine patients was 
reported.25 The reported results show 11% CRs, 44% PRs, 
and 22% SDs.
A number of trials of bevacizumab combined with 
other anticancer compounds were assigned in patients with 
metastatic breast cancer (MBC).26 This report discussed the 
combination of bevacizumab and chemotherapy including 
docetaxel which is known for its synergistic suppression of 
capillary vessel formation. It also discussed a study where 
21 patients with inﬂ  ammatory and locally advanced breast 
cancer (LABC) were assigned a combination therapy of 
bevacizumab and doxorubicin. This particular report showed 
67% PRs, 24% SDs, and 9% PDs. Additional phase II trial 
was conducted in 49 patients to assess the vascular effects on 
tumor regression when using a monotherapy with docetaxel 
as opposed to a combination therapy of bevacizumab and 
docetaxel during the treatment of LABC. This study reported 
14.3% CRs, 65.3% PRs, and 10% disease progression. 
A phase III study of a monotherapy with capecitabine and a 
combination of capecitabine and bevacizumab was conducted 
in 462 patients with MBC.27 This report showed that the 
combination therapy increased the objective response rate 
from 9.1% to 19.8% as opposed to the monotherapy.
A pre-plan for an anticancer 
three-drug compound design
A speciﬁ  c dose of dual ErbB1/ErbB2 inhibitor lapatinib 
(GW572016) was needed to induce poly(adenosine diphos-
phate-ribose) polymerase (PARP) cleavage and DNA frag-
mentation to inhibit activation of EGFR and ErbB2 as well 
as the downstream MAPK and AKT pathways.28 Various 
experiments validated that a concentration higher than the 
inhibitory concentration (IC)50 determines the induction of 
apoptosis. Conversely, small inhibitory effects on EGFR or 
ErbB2 phosphorylation in tumor cells were observed when 
concentrations are below the IC50 value.29
Furthermore, it was reported that for some chronic, physi-
ological diseases, synergism or antagonism at low concentra-
tion level also contribute towards treatment.30 However, for 
infectious diseases or cancer therapies, synergism at high 
effect levels including equilibrium dialysis (ED)90, ED95, or 
ED99, are considered to be more therapeutically appropriate 
as opposed to low effect levels such as ED30 or ED50.
The number of events, which occur during the process of 
killing cancer cells through the combination of two cytotoxic 
agents, is unknown. Evaluating synergism or antagonism and 
the explanation of how or why it happens represents different 
issues.30 Using the latest technological tools, it is possible to 
design the primary, secondary, and tertiary structure of an 
enzyme or a receptor as depicted in Figure 2,8 however, it 
is still hard to design an inhibitor for the drug development 
process. In addition, the prediction of synergism or antago-
nism for enzymes or receptors is even more complex.
A pre-plan for conducting a three-drug combination 
therapy helps to seamlessly analyze two-drug compounds 
before reaching the three-drug compound. To demonstrate this 
scenario, I propose an experiment to design an anticancer three-
drug combination composed of the following compounds: (1) 
an HDAC inhibitor “HDAC/INH”, (2) a VEGF receptor kinase 
inhibitor “VEGFR/INH”, and (3) an EGFR/ERbB2 inhibitor 
“EGFR/ERbB2/INH”. Figure 3 illustrates the design of the 
proposed experiment, in which each inhibitor refers to a drug. 
This proposal includes a set of three two-drug compounds, one 
three-drug compound, and a set of three three-drug compounds 
given as two-drug compounds consecutively.
In this experiment, it is proposed to use three drugs as 
two drugs as they are represented within square brackets in 
Figure 3. The beneﬁ  t of this process is to gather valuable 
information when combining two drugs, which can be vital 
in spawning a three-drug compound. It embodies a process to 
generate novel compounds that incorporates the cytotoxicity 
factors of both compounds, while it helps to identify the most 
valuable candidate that satisﬁ  es the constraints of preclinical 
models. This process also helps to bridge the gap between 
preclinical models and clinical outcome through accurate 
prediction of toxicity levels.
Challenges in translating 
experimental studies into clinical 
trials
The drug development process is characterized by being high-
risk, long-term, and costly. From a pool of 5,000 compound 
candidates entering the ﬁ  rst development phase, only 5 will 
reach clinical testing.31 Furthermore, a new drug enters phase 
1 testing, only after it endures at least 10 years of preclini-
cal experimentation. It has been reported that in the USA, 
the population of adult cancer patients who are eligible to 
participate in clinical trials is between 2% and 3%. Since the 
resources are very limited, drug sponsors search for cases 
from other parts of the world.32
Novel drug developments need to use an improved 
method to deﬁ  ne the optimal biological dose rather than the 
maximum tolerated dose. These methods and studies need Therapeutics and Clinical Risk Management 2009:5 243
Challenging issues in molecular-targeted therapy
to consider additional factors such as pharmacokinetics 
and pharmacodynamics of the compound instead of merely 
tumor size. The design of preclinical models based on these 
considerations and others such as appropriate endpoints and 
surrogate markers of response will lead to prospective clinical 
trials. This will allow preclinical models to predict clinical 
outcome with an adequate accuracy.
There are numerous challenges in translating experimental 
ﬁ  ndings into clinical trials including a growing need to 
identify improved biomarkers that accurately predict the 
risk of the compound-related toxicity. This is associated 
with the quality of the preclinical models in predicting the 
corresponding toxicity. Hence, the use of nonclinical systems 
including animals, tissues slices, cell cultures, and in silico 
models, will not always help to accurately predict toxicity 
levels in humans. Human tumor xenografts grown subcutane-
ously have been used in preclinical testing when performed 
in immune deﬁ  cient mice.33 These models were successful 
XY2 ligand 
Delta-Ex3 Survivin 
Figure 2 Complex receptor-ligand: Delta-Ex3 (a Survivin isoform) and XY2 (an HRas ligand).   This complex has been properly visualized using CheVi (R) (a Linux-based 
Chemical Visualizer), where XY2 ligand is shown docked along Delta-Ex3’s surface and deeply embedded in a particular active site.
Compound composed of three inhibitors: HDAC/INH, VEGFR/ING, 
and EGFR/ErbB2/INH
1) HDAC/INH + VEGFR/INH 
2) VEGFR/INH + EGFR/ErbB2/INH 
1) EGFR/ErbB2/INH + [HDAC/INH + VEGFR/INH] 
2) HDAC/INH + [VEGFR/INH + EGFR/ErbB2/INH] 
HDAC/INH + VEGFR/INH + EGFR/ErbB2/INH 
Set of three two-drug compounds 
One three-drug compound 
Set of three three-drug compounds given as two-drug compounds
Figure 3 Design of the proposed three-drug combination experiment.
Abbreviations: EGFR, epidermal growth factor receptor; ErbB2, epidermal receptor growth factor 2; HDAC, histone deacetylase; INH, inhibitor;   VEGF, vascular endothelial 
growth factor.Therapeutics and Clinical Risk Management 2009:5 244
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in cytotoxic agents.34 However, the validity of these kinds 
of experiments did not reach the expected predictive indi-
cator of clinical activity except when pharmacokinetically 
clinically equivalent drug doses are tested.35 Biomarkers 
that measure the molecular changes that lead to toxicity are 
considered to provide a useful early detection of toxicity. 
This type of biomarkers will help investigators to conduct a 
predictable and successful transition from preclinical studies 
to clinical trials.
Conclusion
This paper describes an anticancer drug design that combines 
three types of drugs as well as the challenges that lay ahead 
in setting up this type of experiment. The proposed three-
drug compound warrants further experiments and clinical 
tests to demonstrate its candidacy among anticancer drugs. 
An analysis of toxicity is also required to be conducted 
on the newly designed compound. This analysis includes 
whether any two drugs, within the thee-drug compound, 
have overlapping or nonoverlapping toxicity, which includes 
gastrointestinal toxicity, cardiotoxicity, renal toxicity, and 
neurotoxicity. However, the generation of newly designed 
compounds with nonoverlapping toxicities may not be valu-
able since this will increase treatment costs and decrease 
patient compliance.
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